Exploratory analysis of the SHARP trial identified baseline plasma concentration of VEGF and Ang2 as independent predictors of survival in patients with advanced HCC treated with sorafenib, although neither predicted response to treatment [12]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.